Cypriot genetics SME commercializing ERC-discovered biomarkers for non-invasive prenatal diagnosis, with focus on methylation-based trisomy 21 detection via ddPCR.
NIPD Genetics is a Cypriot private genetics company specializing in non-invasive prenatal diagnosis (NIPD/NIPT) — the detection of chromosomal conditions in a fetus from a maternal blood sample, with no risk to the pregnancy. Their scientific work centers on discovering and validating molecular biomarkers, particularly microRNA signatures and DNA methylation patterns, that can reliably identify conditions such as trisomy 21 (Down syndrome) before birth. They pair this biomarker research with advanced laboratory platforms, specifically droplet digital PCR (ddPCR), to develop highly sensitive and specific diagnostic tests. Both H2020 projects were ERC Proof of Concept grants, confirming they have prior ERC-funded basic research discoveries and are actively working to translate those into clinical products.
Both H2020 projects — mR-NIPD and Methyl-ddPCR NIPT — are explicitly focused on non-invasive prenatal diagnosis, covering two distinct molecular biomarker approaches across a five-year span.
mR-NIPD targeted ERC-discovered biomarkers (likely microRNA-based) for prenatal diagnosis, while Methyl-ddPCR NIPT targeted DNA methylation patterns as diagnostic markers for trisomy 21.
Methyl-ddPCR NIPT (2021–2022) explicitly applies ddPCR technology to detect trisomy 21 through methylation analysis of cell-free fetal DNA.
The 2021 project is built on differential methylation as the molecular mechanism for distinguishing fetal from maternal DNA in a NIPT context for trisomy 21 detection.
Both grants are ERC Proof of Concept awards — a scheme reserved for researchers who have prior ERC grants and are translating those findings into market-ready applications.
Their first project (2016–2018) focused on validating biomarkers — likely microRNA-based — discovered through earlier ERC-funded research, aimed at non-invasive prenatal diagnosis broadly. By 2021–2022, their work had sharpened considerably: a specific clinical target (trisomy 21), a specific molecular mechanism (DNA methylation), and a specific laboratory platform (droplet digital PCR). This convergence from broad biomarker validation to a defined technology-target-platform combination is a clear maturation signal — the company moved from early-stage research translation toward a focused clinical product development path.
They are moving from proof-of-concept biomarker science toward a defined clinical diagnostic product — a methylation-based NIPT test for trisomy 21 using ddPCR — positioning them as a potential commercial test developer, licensing partner, or technology supplier to clinical genetics labs.
Both H2020 projects were solo coordinator roles under ERC Proof of Concept grants — a funding scheme that by design does not require consortium partners. NIPD Genetics therefore has no recorded H2020 consortium partners, meaning their EU-funded work has been entirely self-contained and investigator-led. A future collaborator should expect to work with a focused, research-driven SME that has not yet operated in multi-partner consortium settings and may be best approached for tightly scoped bilateral technology or licensing arrangements rather than large consortia.
NIPD Genetics has zero recorded H2020 consortium partners across both projects, reflecting the individual-PI structure of ERC Proof of Concept grants rather than a preference for isolation. Their research network, if any, sits outside the H2020 consortium framework and would need to be explored through their ERC grant history or publication record.
NIPD Genetics occupies a rare position: a private SME that has both discovered novel prenatal diagnostic biomarkers through ERC-funded research and is actively commercializing them — something that puts them between academic labs (which discover but rarely commercialize) and diagnostics manufacturers (which scale but rarely originate). Their specific combination of methylation biology expertise and ddPCR platform capability, applied to trisomy 21 detection, makes them a credible partner or acquisition target for IVD companies, hospital genetics networks, or clinical laboratory groups looking to expand their prenatal testing capabilities. For a consortium builder in the genomics or diagnostics space, they bring proprietary biomarker IP alongside demonstrated ERC validation — a combination that is genuinely difficult to replicate.
